Regeneron Pharmaceuticals Inc (NASDAQ:REGN) EVP Neil Stahl sold 9,853 shares of the stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $305.74, for a total transaction of $3,012,456.22. Following the sale, the executive vice president now owns 47,450 shares in the company, valued at approximately $14,507,363. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of NASDAQ REGN traded up $1.23 during mid-day trading on Wednesday, reaching $305.85. 780,493 shares of the company traded hands, compared to its average volume of 782,744. Regeneron Pharmaceuticals Inc has a fifty-two week low of $291.10 and a fifty-two week high of $442.00. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.58 and a quick ratio of 3.78. The firm has a market capitalization of $33.35 billion, a PE ratio of 15.45, a P/E/G ratio of 1.44 and a beta of 1.08.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $4.45 EPS for the quarter, missing the Zacks’ consensus estimate of $5.24 by ($0.79). Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The company had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.76 billion. During the same quarter in the prior year, the business earned $4.67 EPS. Regeneron Pharmaceuticals’s revenue was up 13.3% compared to the same quarter last year. Sell-side analysts anticipate that Regeneron Pharmaceuticals Inc will post 18.37 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Smithfield Trust Co. acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. Whittier Trust Co. boosted its stake in Regeneron Pharmaceuticals by 195.7% in the 4th quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 45 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $29,000. Citizens Financial Group Inc RI acquired a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $30,000. Finally, AdvisorNet Financial Inc lifted its position in Regeneron Pharmaceuticals by 208.0% in the 4th quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 52 shares in the last quarter. Institutional investors and hedge funds own 67.63% of the company’s stock.
Several equities research analysts recently weighed in on REGN shares. TheStreet upgraded shares of Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, January 17th. Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 price objective on the stock in a research note on Thursday, February 7th. BidaskClub lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 7th. UBS Group dropped their price target on shares of Regeneron Pharmaceuticals from $480.00 to $440.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Finally, Morgan Stanley dropped their price target on shares of Regeneron Pharmaceuticals from $420.00 to $389.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 8th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $404.88.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Read More: Balanced Fund
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.